11 Jan 2019 Research

Lymphoma: Understanding relapse and treatment resistance

What is this research looking at?

Our immune system is remarkable. It is made up of many different types of immune cells that work together to protect the body from infection by pathogens such as bacteria, viruses and parasites.

We are investigating what happens when a certain type of cell in the immune system, known as B cells, starts growing out of control and develops into blood cancers such as leukaemia, lymphoma and myeloma.

We want to know what happens when B cells mature normally from precursor cells in the bone marrow and discover what has gone wrong when they turn into cancer cells instead.

Considerable success has been achieved in the treatment of lymphoma. However, a significant unmet need remains: roughly 40% of patients either do not respond to treatment or the condition recurs after treatment. Currently, our ability to predict which patients will fail treatment is poor.

By taking a detailed look at B cells as they develop and specialise, we can spot small groups of dangerous cells that are particularly likely to turn into cancer and identify the genetic faults that drive B cells to grow out of control.

We are using our knowledge to create new models for the development of B cells and blood cancers in the lab, so we can find new ways to treat or even prevent these deadly diseases.

Our research uses a model of lymphoma to test the response to treatments and development of resistance. A main advantage of the model is that we can interrogate these questions on a well-defined scenario and can perform iterative tests and predictions. Further, the model generated in this project will allow initial testing of novel treatments.

What could this mean for people with leukaemia?

This research could inform the medical decision of when to use combination and novel therapies for patients with a higher probability of developing resistance to standard treatment, alongside bringing safer treatments to patients.

Official project title: Development of a model system to study diffuse large B cell lymphoma clonal evolution

Related posts

Beloved actor who beat leukaemia now fronting charity TV ad to help raise vital funds

19 December 2023

Beloved actor who beat leukaemia now fronting charity TV ad to help raise vital funds

83-year-old actor Richard Tate will appear on screens from 26th December onwards to support Leukaemia UK’s call for legacy pledges (otherwise known as gifts in Wills), after surviving leukaemia thanks…

Statement from Leukaemia UK on the death of Her Majesty Queen Elizabeth II

8 September 2022

Statement from Leukaemia UK on the death of Her Majesty Queen Elizabeth II

On behalf of the Leukaemia UK team, Chair of Trustees, Chris Corbin OBE, has made the following statement: “We are extremely saddened to hear the news of the death of…

International Childhood Cancer Day: Dr Samanta Mariani reflects on her research into infant leukaemia

11 February 2022

International Childhood Cancer Day: Dr Samanta Mariani reflects on her research into infant leukaemia

On International Childhood Cancer Day, Dr Samanta Mariani reflects on her research into infant leukaemia, what drives her in her work and her hopes for the future.

Leukaemia UK bolsters research and advocacy team, in support of ambitious strategy to accelerate progress in the diagnosis, treatment, and care of leukaemia

30 January 2024

Leukaemia UK bolsters research and advocacy team, in support of ambitious strategy to accelerate progress in the diagnosis, treatment, and care of leukaemia

Leukaemia UK is pleased to announce Dr Simon Ridley as the new Director of Research and Advocacy and Dr Georgia Papacleovoulou as the organisation’s first ever Head of Policy and…